Extended Data Fig. 1: Analyzing amino acid transporters during dendritic cell efferocytosis.
From: Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes
a, SLC programs modulated in dendritic cells during efferocytosis of apoptotic cells compared to sterile phagocytosis. RNAseq was performed on primary BMDCs after engulfment apoptotic human Jurkat cells or beads. The heatmap illustrates SLCs upregulated and downregulated during dendritic cell efferocytosis. b, Uptake of CypHer5E- labelled apoptotic Jurkat cells by dendritic cells (BMDC) silenced for Slc7a1 expression (n = 2 per condition). c, Slc7a5 siRNA targeting in dendritic cells does not significantly affect apoptotic cell uptake as assessed by Incucyte Live-cell imaging (n = 4 per group). d, Efferocytosis of TAMRA-labelled apoptotic Jurkat cells by dendritic cells treated with different concentrations of the Slc7a5 inhibitor, JPH-203 (n = 2 per condition). e, Kinetics of efferocytosis by BMDC treated with 3 μM JPH-203 (n = 3 per condition). f, Measurement of degradation of TAMRA (pH insensitive) and Cell Trace Violet (pH sensitive) co-labelled apoptotic targets after efferocytosis by Slc7a11 KO and WT dendritic cells (n = 4 per group). Dendritic cells were incubated with apoptotic targets at a 1:5 phagocyte:target ratio for four hours. Floating bars show minimum to maximum values with all independent replicates, line denotes mean. g, Kinetics of efferocytosis by Slc7a11 WT and Slc7a11 KO bone marrow-derived macrophages with or without erastin treatment (n = 4 per group). ns: not significant; via One-way ANOVA with Tukey’s multiple comparisons test. h, Efferocytosis by peritoneal macrophages after Slc7a11 inhibition via erastin. (n = 8 per condition; P = 0.19, with paired, two-tailed t-test). c, e, g, All live-cell imaging data are expressed as mean ± SEM.
